Cargando…
P1108: HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430686/ http://dx.doi.org/10.1097/01.HS9.0000847300.61295.fe |
_version_ | 1784779843069542400 |
---|---|
author | Fried, S. Besser, M. J. Shkury, E. Yerushalmi, R. Shem-Tov, N. Danylesko, I. Jacoby, E. Itzhaki, O. Shouval, R. Kedmi, M. Shimoni, A. Nagler, A. Avigdor, A. |
author_facet | Fried, S. Besser, M. J. Shkury, E. Yerushalmi, R. Shem-Tov, N. Danylesko, I. Jacoby, E. Itzhaki, O. Shouval, R. Kedmi, M. Shimoni, A. Nagler, A. Avigdor, A. |
author_sort | Fried, S. |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-9430686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-94306862022-08-31 P1108: HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA Fried, S. Besser, M. J. Shkury, E. Yerushalmi, R. Shem-Tov, N. Danylesko, I. Jacoby, E. Itzhaki, O. Shouval, R. Kedmi, M. Shimoni, A. Nagler, A. Avigdor, A. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430686/ http://dx.doi.org/10.1097/01.HS9.0000847300.61295.fe Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
spellingShingle | Posters Fried, S. Besser, M. J. Shkury, E. Yerushalmi, R. Shem-Tov, N. Danylesko, I. Jacoby, E. Itzhaki, O. Shouval, R. Kedmi, M. Shimoni, A. Nagler, A. Avigdor, A. P1108: HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA |
title | P1108: HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA |
title_full | P1108: HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA |
title_fullStr | P1108: HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA |
title_full_unstemmed | P1108: HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA |
title_short | P1108: HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA |
title_sort | p1108: high complete response rate following point-of-care anti cd19 car t-cell therapy in patients with relapsed/refractory follicular lymphoma |
topic | Posters |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430686/ http://dx.doi.org/10.1097/01.HS9.0000847300.61295.fe |
work_keys_str_mv | AT frieds p1108highcompleteresponseratefollowingpointofcareanticd19cartcelltherapyinpatientswithrelapsedrefractoryfollicularlymphoma AT bessermj p1108highcompleteresponseratefollowingpointofcareanticd19cartcelltherapyinpatientswithrelapsedrefractoryfollicularlymphoma AT shkurye p1108highcompleteresponseratefollowingpointofcareanticd19cartcelltherapyinpatientswithrelapsedrefractoryfollicularlymphoma AT yerushalmir p1108highcompleteresponseratefollowingpointofcareanticd19cartcelltherapyinpatientswithrelapsedrefractoryfollicularlymphoma AT shemtovn p1108highcompleteresponseratefollowingpointofcareanticd19cartcelltherapyinpatientswithrelapsedrefractoryfollicularlymphoma AT danyleskoi p1108highcompleteresponseratefollowingpointofcareanticd19cartcelltherapyinpatientswithrelapsedrefractoryfollicularlymphoma AT jacobye p1108highcompleteresponseratefollowingpointofcareanticd19cartcelltherapyinpatientswithrelapsedrefractoryfollicularlymphoma AT itzhakio p1108highcompleteresponseratefollowingpointofcareanticd19cartcelltherapyinpatientswithrelapsedrefractoryfollicularlymphoma AT shouvalr p1108highcompleteresponseratefollowingpointofcareanticd19cartcelltherapyinpatientswithrelapsedrefractoryfollicularlymphoma AT kedmim p1108highcompleteresponseratefollowingpointofcareanticd19cartcelltherapyinpatientswithrelapsedrefractoryfollicularlymphoma AT shimonia p1108highcompleteresponseratefollowingpointofcareanticd19cartcelltherapyinpatientswithrelapsedrefractoryfollicularlymphoma AT naglera p1108highcompleteresponseratefollowingpointofcareanticd19cartcelltherapyinpatientswithrelapsedrefractoryfollicularlymphoma AT avigdora p1108highcompleteresponseratefollowingpointofcareanticd19cartcelltherapyinpatientswithrelapsedrefractoryfollicularlymphoma |